Latest Whitepapers

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.

Download this whitepaper to discover how high-throughput flow cytometry can provide quantitative data on binding, antibody internalization and antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and T-cell activation.

Primary antibody labeling simplifies assays, enables multiplexing and eliminates the cross-reactivity seen with secondary antibodies – helping you to streamline your workflow, increase your flexibility and improve reproducibility.

Creating and bringing new drugs to the market can bring huge productivity challenges as the already complex drug development process becomes lengthier and more expensive.

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market.

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.

Download your whitepaper to learn more about modeling COVID-19 infection in organoids, how to combat COVID-19 variants as well as the future of organoid technology.

Liquid biopsies are rapidly gaining traction and becoming a standard of care for cancer. They are an attractive alternative to invasive, painful, costly tissue biopsies and can facilitate real-time monitoring while providing insight into the disease state, even for tissues that are difficult to access, such as brain cancers.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.

Immuno-oncology research investigates how the immune system interacts with cancer cells within the tumor microenvironment, a process which is not fully understood.